http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-107254546-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-106 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-156 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-11 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-6886 |
| filingDate | 2017-08-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2020-11-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2020-11-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-107254546-B |
| titleOfInvention | SNP marker related to breast cancer neoadjuvant chemotherapy curative effect and application thereof |
| abstract | The invention relates to an SNP marker related to the curative effect of breast cancer neoadjuvant chemotherapy and application thereof, in particular to an SNP marker related to the curative effect of breast cancer neoadjuvant taxol-based scheme chemotherapy and application thereof, wherein the SNP marker comprises an rs2981578 site on an FGFR2 gene and an rs1966265 site on an FGFR4 gene. As the application of the SNP marker, the invention also provides a kit for detecting or predicting the neoadjuvant chemotherapy curative effect of the breast cancer. The invention can be used for detecting or predicting the chemotherapy curative effect of the breast cancer neoadjuvant taxol scheme, provides basis for realizing individual treatment of patients, and is used for guiding the individual treatment, improving the prognosis of the patients and improving the effectiveness and the safety of clinical medication. |
| priorityDate | 2017-08-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 42.